Staging and Prognosis of Thyroid Cancer

  • Joanna Klubo-GwiezdzinskaEmail author


The incidence of thyroid cancer has tripled worldwide over the past 20 years. Appropriate risk stratification guides the distinction between the patients with indolent thyroid cancer who are the candidates for conservative approach and patients at risk of dying from thyroid cancer necessitating aggressive therapy. Initial risk estimates are used to guide initial therapeutic approach, while evaluation of the response to treatment helps in the establishment of the individual, patient-tailored approach to subsequent management and follow-up. This chapter describes currently utilized staging systems evaluating the predictors of overall survival (OS), disease-specific survival (DSS), as well as the risk of thyroid cancer recurrence and disease-free survival.


Prognosis Recurrence rate Mortality Thyroid cancer 


  1. 1.
    Cancer facts and figures. 2016.Google Scholar
  2. 2.
    Vaccarella S, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375(7):614–7.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3. Scholar
  4. 4.
    Elisei R, Pinchera A. Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol. 2012;8(8):466–75.CrossRefGoogle Scholar
  5. 5.
    Yang L, Shen W, Sakamoto N. Population-based study evaluating and predicting the probability of death resulting from thyroid cancer and other causes among patients with thyroid cancer. J Clin Oncol. 2013;31(4):468–74.CrossRefGoogle Scholar
  6. 6.
    Verburg FA, et al. Life expectancy is reduced in differentiated thyroid cancer patients >/= 45 years old with extensive local tumor invasion, lateral lymph node, or distant metastases at diagnosis and normal in all other DTC patients. J Clin Endocrinol Metab. 2013;98(1):172–80.CrossRefGoogle Scholar
  7. 7.
    Haugen BR, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104(6):947–53.CrossRefGoogle Scholar
  9. 9.
    Byar DP, et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid cancer cooperative group. Eur J Cancer. 1979;15(8):1033–41.CrossRefGoogle Scholar
  10. 10.
    Lerch H, et al. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol. 1997;15(5):2067–75.CrossRefGoogle Scholar
  11. 11.
    Podnos YD, et al. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg. 2005;71(9):731–4.Google Scholar
  12. 12.
    Zaydfudim V, et al. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144(6):1070–7. discussion 1077-8.CrossRefGoogle Scholar
  13. 13.
    Adam MA, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol. 2015;33(21):2370–5.CrossRefGoogle Scholar
  14. 14.
    Londero SC, et al. Papillary thyroid carcinoma in Denmark, 1996–2008: outcome and evaluation of established prognostic scoring systems in a prospective national cohort. Thyroid. 2015;25(1):78–84.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Volante M, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer. 2004;100(5):950–7.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Tanase K, et al. The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancer. Clin Endocrinol (Oxf). 2015.Google Scholar
  17. 17.
    Hay ID, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102(6):1088–95.Google Scholar
  18. 18.
    Pasieka JL, et al. Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery. 1992;112(6):1154–9. discussion 1159-60.Google Scholar
  19. 19.
    Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery. 1994;116(6):1036–40. discussion 1040-1.Google Scholar
  20. 20.
    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–28.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sherman SI, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83(5):1012–21.CrossRefGoogle Scholar
  22. 22.
    Beenken S, et al. Extent of surgery for intermediate-risk well-differentiated thyroid cancer. Am J Surg. 2000;179(1):51–6.CrossRefGoogle Scholar
  23. 23.
    Pathak KA, et al. Comparing a thyroid prognostic nomogram to the existing staging systems for prediction risk of death from thyroid cancers. Eur J Surg Oncol. 2016;42(10):1491–6.CrossRefGoogle Scholar
  24. 24.
    Pathak KA, et al. Prognostic nomograms to predict oncological outcome of thyroid cancers. J Clin Endocrinol Metab. 2013;98(12):4768–75.CrossRefGoogle Scholar
  25. 25.
    DeGroot LJ, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414–24.CrossRefGoogle Scholar
  26. 26.
    Noguchi S, Murakami N, Kawamoto H. Classification of papillary cancer of the thyroid based on prognosis. World J Surg. 1994;18(4):552–7. discussion 558.CrossRefGoogle Scholar
  27. 27.
    Yildirim E. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. J Am Coll Surg. 2005;200(3):378–92.CrossRefGoogle Scholar
  28. 28.
    Akslen LA. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer. 1993;72(9):2680–5.CrossRefGoogle Scholar
  29. 29.
    Sugitani I, et al. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135(2):139–48.CrossRefGoogle Scholar
  30. 30.
    Ganly I, et al. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid. 2015;25(10):1106–14.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Bischoff LA, et al. Is above age 45 appropriate for upstaging well-differentiated papillary thyroid cancer? Endocr Pract. 2013;19(6):995–7.CrossRefGoogle Scholar
  32. 32.
    Nixon IJ, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid. 2016;26(3):373–80.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Hendrickson-Rebizant J, et al. Identifying the most appropriate age threshold for TNM stage grouping of well-differentiated thyroid cancer. Eur J Surg Oncol. 2015;41(8):1028–32.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Mazurat A, et al. The age factor in survival of a population cohort of well-differentiated thyroid cancer. Endocr Connect. 2013;2(3):154–60.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    McLeod DS, et al. Reassessing the NTCTCS staging systems for differentiated thyroid cancer, including age at diagnosis. Thyroid. 2015;25(10):1097–105.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Nikiforov YE, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023–9.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Nikiforov YE, Biddinger PW, Lester DR, Thompson MD. Diagnostic pathology and molecular genetics of the thyroid. 1st ed. Lippincott; 2012. p. 152–82.Google Scholar
  38. 38.
    Leung AK, Chow SM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope. 2008;118(1):32–8.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Ghossein RA, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid. 2007;17(7):655–61.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Morris LG, et al. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid. 2010;20(2):153–8.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Chen JH, et al. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Mod Pathol. 2011;24(5):739–49.CrossRefGoogle Scholar
  42. 42.
    Asioli S, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010;34(1):44–52.CrossRefGoogle Scholar
  43. 43.
    Shi X, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab. 2016;101(1):264–74.PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Asioli S, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol. 2010;23(9):1269–78.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Jonklaas J, et al. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 2012;97(6):E878–87.PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Nilubol N, Kebebew E. Should small papillary thyroid cancer be observed? A population-based study. Cancer. 2015;121(7):1017–24.CrossRefGoogle Scholar
  47. 47.
    Papaleontiou M, Haymart MR. New insights in risk stratification of differentiated thyroid cancer. Curr Opin Oncol. 2014;26(1):1–7.PubMedCentralCrossRefPubMedGoogle Scholar
  48. 48.
    Qubain SW, et al. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery. 2002;131(3):249–56.CrossRefGoogle Scholar
  49. 49.
    Schneider DF, Chen H, Sippel RS. Impact of lymph node ratio on survival in papillary thyroid cancer. Ann Surg Oncol. 2013;20(6):1906–11.CrossRefGoogle Scholar
  50. 50.
    Smith VA, Sessions RB, Lentsch EJ. Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival? Experience from the SEER database. J Surg Oncol. 2012;106(4):357–62.CrossRefGoogle Scholar
  51. 51.
    Schneider DF, et al. Lymph node metastases do not impact survival in follicular variant papillary thyroid cancer. Ann Surg Oncol. 2015;22(1):158–63.CrossRefGoogle Scholar
  52. 52.
    Hay ID, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114(6):1050–7. discussion 1057-8.Google Scholar
  53. 53.
    Qu N, et al. Number of tumor foci predicts prognosis in papillary thyroid cancer. BMC Cancer. 2014;14:914.PubMedCentralCrossRefPubMedGoogle Scholar
  54. 54.
    Riss JC, et al. Prognostic impact of tumour multifocality in thyroid papillary microcarcinoma based on a series of 160 cases. Eur Ann Otorhinolaryngol Head Neck Dis. 2012;129(4):175–8.CrossRefGoogle Scholar
  55. 55.
    Connor MP, Wells D, Schmalbach CE. Variables predictive of bilateral occult papillary microcarcinoma following total thyroidectomy. Otolaryngol Head Neck Surg. 2011;144(2):210–5.CrossRefGoogle Scholar
  56. 56.
    Wong RM, Bresee C, Braunstein GD. Comparison with published systems of a new staging system for papillary and follicular thyroid carcinoma. Thyroid. 2013;23(5):566–74.CrossRefGoogle Scholar
  57. 57.
    Lo CY, et al. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Ann Surg. 2005;242(5):708–15.PubMedCentralCrossRefPubMedGoogle Scholar
  58. 58.
    Lang BH, et al. Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. Ann Surg. 2007;246(1):114–21.PubMedCentralCrossRefPubMedGoogle Scholar
  59. 59.
    Lang BH, et al. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245(3):366–78.PubMedCentralCrossRefPubMedGoogle Scholar
  60. 60.
    Ito Y, et al. Static and dynamic prognostic factors of papillary thyroid carcinoma. Endocr J. 2014;61(12):1145–51.CrossRefGoogle Scholar
  61. 61.
    Saindane AM. Pitfalls in the staging of cancer of thyroid. Neuroimaging Clin N Am. 2013;23(1):123–45.CrossRefGoogle Scholar
  62. 62.
    Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am. 2014;43(2):401–21.CrossRefGoogle Scholar
  63. 63.
    Lang BH, Wong CK. Validation and comparison of nomograms in predicting disease-specific survival for papillary thyroid carcinoma. World J Surg. 2015;39(8):1951–8.CrossRefGoogle Scholar
  64. 64.
    Tuttle RM, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20(12):1341–9.PubMedCentralCrossRefPubMedGoogle Scholar
  65. 65.
    Vaisman F, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf). 2012;77(1):132–8.CrossRefGoogle Scholar
  66. 66.
    Castagna MG, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011;165(3):441–6.CrossRefGoogle Scholar
  67. 67.
    Berger F, et al. Diagnostic 131I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and long-term follow-up. Eur J Nucl Med Mol Imaging. 2011;38(3):451–8.CrossRefGoogle Scholar
  68. 68.
    Malandrino P, et al. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab. 2011;96(6):1703–9.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Soyluk O, et al. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment. Thyroid. 2011;21(12):1301–8.CrossRefGoogle Scholar
  70. 70.
    Han JM, et al. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid. 2012;22(8):784–90.PubMedCentralCrossRefPubMedGoogle Scholar
  71. 71.
    Rosario PW, et al. Value of repeat stimulated thyroglobulin testing in patients with differentiated thyroid carcinoma considered to be free of disease in the first year after ablation. Thyroid. 2012;22(5):482–6.CrossRefGoogle Scholar
  72. 72.
    Brassard M, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab. 2011;96(5):1352–9.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Klubo-Gwiezdzinska J, et al. Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission? Clin Endocrinol (Oxf). 2011;74(1):111–7.CrossRefGoogle Scholar
  74. 74.
    Verburg FA, et al. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(2):276–83.CrossRefGoogle Scholar
  75. 75.
    !!! INVALID CITATION !!!Google Scholar
  76. 76.
    Wong H, et al. Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation? Ann Surg Oncol. 2012;19(11):3479–85.PubMedCentralCrossRefPubMedGoogle Scholar
  77. 77.
    Miyauchi A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011;21(7):707–16.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Yim JH, et al. The outcomes of first reoperation for locoregionally recurrent/persistent papillary thyroid carcinoma in patients who initially underwent total thyroidectomy and remnant ablation. J Clin Endocrinol Metab. 2011;96(7):2049–56.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Tufano RP, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore). 2012;91(5):274–86.CrossRefGoogle Scholar
  80. 80.
    Elisei R, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97(12):4390–8.CrossRefGoogle Scholar
  81. 81.
    Fernandez IJ, et al. Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngol Head Neck Surg. 2013;148(6):919–25.CrossRefGoogle Scholar
  82. 82.
    Tavares C, et al. Endocrine tumours: genetic predictors of thyroid cancer outcome. Eur J Endocrinol. 2016;174(4):R117–26.CrossRefGoogle Scholar
  83. 83.
    Niederer-Wust SM, et al. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer. Surgery. 2015;157(1):119–25.CrossRefGoogle Scholar
  84. 84.
    Song YS, et al. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer. 2016;122(9):1370–9.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Xing M, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718–26.PubMedCentralCrossRefPubMedGoogle Scholar
  86. 86.
    Ortiz S, et al. Recurrent papillary thyroid cancer: analysis of prognostic factors including the histological variant. Eur J Surg. 2001;167(6):406–12.CrossRefGoogle Scholar
  87. 87.
    Passler C, et al. Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution. Ann Surg. 2003;237(2):227–34.PubMedCentralPubMedGoogle Scholar
  88. 88.
    Brierley JD, et al. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer. 1997;79(12):2414–23.CrossRefGoogle Scholar
  89. 89.
    Voutilainen PE, et al. AMES, MACIS and TNM prognostic classifications in papillary thyroid carcinoma. Anticancer Res. 2003;23(5b):4283–8.Google Scholar
  90. 90.
    D’Avanzo A, et al. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid. 2004;14(6):453–8.CrossRefGoogle Scholar
  91. 91.
    Lang BH, et al. Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre. Endocr Relat Cancer. 2007;14(1):29–42.CrossRefGoogle Scholar
  92. 92.
    Pitoia F, et al. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. Thyroid. 2013;23(11):1401–7.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Georgetown University School of MedicineWashington, DCUSA
  2. 2.National Institutes of Health—National Institute of Diabetes and Digestive and Kidney DiseaseBethesdaUSA

Personalised recommendations